for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

BRIEF-Basilea Starts Phase 1/2 Study With Derazantinib In Urothelial Cancer

Aug 13 (Reuters) - BASILEA PHARMACEUTICA AG:

* BASILEA STARTS PHASE 1/2 STUDY WITH DERAZANTINIB IN UROTHELIAL CANCER Source text for Eikon: Further company coverage: (Gdynia Newsroom)

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up